Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Ovarian Cancer & Adenocarcinoma Development
Key Molecular Features of MUC16
MUC16 (also known as CA125) is a giant transmembrane glycoprotein encoded by the MUC16 gene. It contains three SEA domains (SEA 1, SEA 2, SEA 3) crucial for protein-protein interactions and is heavily O‑glycosylated. Clinically relevant genetic variants include dbSNP:rs17000957, rs17000950, and rs10411228. The majority of its extracellular domain is shed into the bloodstream as CA125; the membrane‑proximal C‑terminal retained domain is the therapeutic target for next‑generation drugs.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MUC16 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Retained Domain) | MUC16 C‑terminal ECD‑Fc / Mutant Protein, >95% purity, Endotoxin <1EU/µg, HEK293 expressed (native glycosylation). | View MUC16 Products |
| Gene Delivery | MUC16 Full‑Length Lentivirus Premade Particles (ORF encoding transmembrane domain) for stable cell line construction; ideal for internalization assays. | View MUC16 Products |
| Benchmark Ab | Anti‑MUC16 (Sequence of Clinical Benchmark e.g., Upifitamab), recombinant positive control, human IgG1. | View MUC16 Products |
| Validator | MUC16 siRNA Set (3 target‑specific + 1 control) for knockdown verification and specificity confirmation. | View MUC16 Products |
| Related Target A | FOLR1 – synergistic target for ovarian cancer combination therapies. | View FOLR1 Products |
| Related Target B | MSLN – known binding partner mediating cell adhesion and metastasis; essential for competition assays. | View MSLN Products |
| Related Target C | MUC1 – co‑expressed mucin in ovarian cancer; relevant for dual‑targeting strategies. | View MUC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Shedding Interference (CA‑125 vs Retained Domain) | Specific Truncation Proteins strictly representing the membrane‑proximal retained domain available with >95% purity; C‑terminal Domain Antigen excludes tandem repeat regions. |
| Native Glycosylation Requirements | HEK293 Expressed systems ensuring complex human O‑glycosylation patterns. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for specificity checks and target validation. |
| Cross‑species Toxicology | Human/Mouse/Cynomolgus Ortholog Proteins (C‑terminal domain) available with >95% purity. |
| Internalization Efficiency (ADC Payload Delivery) | Lentivirus for Stable Cell Line construction (Flow Cytometry/Confocal compatible) + High‑purity ECD for pH‑dependent binding assays. |
| Mesothelin Competition | MSLN Recombinant Protein available for competitive binding and co‑immunoprecipitation studies. |
Live MUC16 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MUC16‑targeted therapeutics is intensifying, with major players shifting focus from traditional mAbs to Bispecific T‑cell Engagers, CAR‑T therapies, and ADCs. Because the bulk of MUC16 extracellular domain is shed into the bloodstream (clinically monitored as CA‑125), first‑generation therapies often suffered from target sink effects. As leading candidates (e.g., Ubamatamab from Regeneron, Upifitamab Rilsodotin from Mersana, STRO‑002 from Sutro) advance through the clinic, the next wave of R&D is targeting the non‑cleaved, membrane‑retained C‑terminal domain of MUC16, requiring highly specific reagents to validate true cell‑surface binding and internalization. Additionally, mesothelin (MSLN) interaction is a key mechanism for tumor adhesion and metastasis, driving development of MUC16–MSLN competitive binders. Combination therapies with PARP inhibitors or anti‑angiogenic agents are also being explored, expanding the need for comprehensive assay panels.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific Antibody | Regeneron (Ubamatamab), Preclinical programs | Ovarian Cancer, Solid Tumors | Heterodimer Validation (Need High‑Purity Retained Domain Proteins) |
| CAR‑T | Kite Pharma / BioNTech, Academic/Early Biotech | Advanced Solid Tumors, Ovarian Cancer | Cell‑based Validation (Need Lentivirus for Stable Cell Lines) |
| ADC (Dolaflexin/SC239) | Mersana (Upifitamab Rilsodotin), Sutro (Luveltamab Tazevibulin) | Platinum‑resistant Ovarian Cancer | Internalization Assay (Need high‑purity C‑terminal ECD‑Fc); Mesothelin competition panel |
| ADC (Cleavable Linker) | Biogen, Novartis (legacy) | Fallopian Tube, Primary Peritoneal | Shed Antigen Interference Test (Need Non‑shed domain protein) |